Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

(2019) Timothy F Cloughesy et al.   NEURO-ONCOLOGY

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma

(2018) Benjamin M Ellingson et al.   NEURO-ONCOLOGY

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma

(2018) Benjamin M Ellingson et al.   NEURO-ONCOLOGY

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo

(2018) Benjamin M Ellingson et al.   NEURO-ONCOLOGY

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials

(2017) Shou-Bo Yang et al.   Oncotarget

Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma

(2016) Benjamin M. Ellingson et al.   CANCER

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma

(2016) Shiao-Pei Weathers et al.   JOURNAL OF NEURO-ONCOLOGY

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

(2016) Benjamin M. Ellingson et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013

(2016) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

(2015) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices

(2015) Clara Chen et al.   JOURNAL OF NEURO-ONCOLOGY

VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme

(2015) Aleksandra Gruslova et al.   JOURNAL OF NEURO-ONCOLOGY

Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma

(2015) Johnny Duerinck et al.   JOURNAL OF NEUROLOGY

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

(2015) Kathryn M. Field et al.   NEURO-ONCOLOGY

Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: TheintervalRPackage

(2015) Michael P. Fay et al.   Journal of Statistical Software

Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

(2014) Kathryn M. Field et al.   CANCER

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors

(2013) A. J. Brenner et al.   CLINICAL CANCER RESEARCH

Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial

(2013) Benjamin M. Ellingson et al.   RADIOLOGY

Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma

(2012) M. Nagane et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage therapy with single agent bevacizumab for recurrent glioblastoma

(2009) Marc C. Chamberlain et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY